CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating ...
Enrollment continuing to progress toward an interim analysis, planned when 30-50% of subjects reach the primary endpoint expected mid-year 2023 HOUSTON, Feb. 7, 2023 /PRNewswire/ -- CNS PHARMACEUTICALS Inc. (NASDAQ: CNSP) ("CNS" or the …